Oppenheimer reiterated their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a report published on Sunday, TipRanks reports. They currently have a $29.00 price target on the biotechnology company’s stock. Oppenheimer also issued estimates for Seres Therapeutics’ Q2 2021 earnings at ($0.30) EPS, Q3 2021 earnings at ($0.32) EPS and Q4 2021 earnings at ($0.33) EPS.

Several other research analysts have also recently issued reports on the stock. ValuEngine raised shares of Seres Therapeutics from a hold rating to a buy rating in a report on Tuesday, August 11th. BidaskClub cut shares of Seres Therapeutics from a buy rating to a hold rating in a report on Saturday, July 18th. Chardan Capital lifted their target price on shares of Seres Therapeutics from $12.50 to $32.50 and gave the stock a buy rating in a report on Monday, August 10th. Zacks Investment Research lowered shares of Seres Therapeutics from a buy rating to a sell rating in a research note on Thursday, July 30th. Finally, Canaccord Genuity lifted their price target on shares of Seres Therapeutics from $11.00 to $38.00 and gave the stock a buy rating in a research note on Monday, August 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $30.64.

Shares of NASDAQ:MCRB opened at $27.32 on Friday. The company has a market capitalization of $2.08 billion, a PE ratio of -26.27 and a beta of 4.50. The business has a fifty day moving average price of $18.90 and a 200-day moving average price of $7.86. Seres Therapeutics has a 1-year low of $2.52 and a 1-year high of $33.00.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $6.05 million for the quarter, compared to analyst estimates of $9.67 million. On average, analysts expect that Seres Therapeutics will post -1.06 EPS for the current year.

Hedge funds have recently made changes to their positions in the company. Cresset Asset Management LLC bought a new stake in Seres Therapeutics during the second quarter valued at approximately $58,000. Citigroup Inc. grew its position in Seres Therapeutics by 15.0% during the first quarter. Citigroup Inc. now owns 15,802 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 2,060 shares during the period. Trexquant Investment LP bought a new stake in Seres Therapeutics during the second quarter valued at approximately $318,000. Advisor Group Holdings Inc. bought a new stake in Seres Therapeutics during the first quarter valued at approximately $38,000. Finally, FDx Advisors Inc. bought a new stake in Seres Therapeutics during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 94.42% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Read More: High-Yield Dividend Stocks

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.